Ergomed PLC (LON:ERGO) has said it is to provide drug safety services to assess the effect of a rheumatoid arthritis treatment on patients with severe COVID-19 infection caused by coronavirus.
The company is providing the services through its specialist pharmacovigilance provider, PrimeVigilance, as part of an ongoing clinical trial.
"COVID-19 represents a severe and pressing challenge for all involved in the development of new medicines and we are proud to be expanding our involvement in the field by bringing our expertise in drug safety and pharmacovigilance to this programme,” Dr Miroslav Reljanović, the executive chairman of Ergomed said in a statement.
“The rapid initiation of clinical trials and establishment of appropriate safety monitoring will be critical to providing new treatments which may improve outcomes for patients," he added.